Cannabis shows little promise for chemotherapy nerve pain relief

Chemotherapy-induced peripheral neuropathy (CIPN) is a severe side effect that affects many cancer patients, causing chronic pain and reduced quality of life. This systematic review examined whether cannabis-based medicinal products could help treat or prevent CIPN by analyzing randomized controlled trials with 68 participants. Researchers investigated three main types of interventions: nabiximols (a cannabis extract), oral cannabidiol (CBD), and topical CBD. Although preclinical studies showed promise, suggesting cannabinoids work through multiple pathways including reducing neuroinflammation and oxidative stress, the clinical results were disappointing.

The review found that none of the three completed trials showed improvement in pain or quality of life compared to placebo. While side effects were generally mild to moderate—most commonly fatigue, dizziness, and dry mouth—they didn't outweigh a lack of therapeutic benefit. The researchers faced significant limitations: only three completed trials existed, studies used different measurements and follow-up periods, and there were only three more trials still ongoing. These differences made it impossible to combine the data for a comprehensive meta-analysis.

The conclusion is clear: current evidence is insufficient to recommend cannabis products for routine CIPN treatment. However, this isn't the final word—the field remains early and more rigorous research is needed. Larger, well-designed trials with standardized pain measurements and longer follow-up periods could clarify whether cannabinoids might help specific patient populations or when used in particular ways. For cancer patients with CIPN, this means existing treatments and other interventions remain the primary options until stronger evidence emerges.